Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2026 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

sumitomo dainippon pharma - SMDPY

SMDPY

Close Chg Chg %
11.45 3.30 28.82%

Closed Market

14.75

+3.30 (28.82%)

Volume: 250.00

Last Updated:

Feb 4, 2026, 3:39 PM EDT

Trade Now

Company Overview: sumitomo dainippon pharma - SMDPY

SMDPY Key Data

Open

$14.75

 Day Range

14.75 - 14.75

52 Week Range

4.78 - 14.75

 Market Cap

$5.86B

Shares Outstanding

397.29M

 Public Float

N/A

Beta

0.44

 Rev. Per Employee

N/A

P/E Ratio

7.86

 EPS

$1.88

Yield

0.00%

 Dividend

$0.03

EX-DIVIDEND DATE

Mar 30, 2023

 SHORT INTEREST

N/A

AVERAGE VOLUME

11.45

  

SMDPY Performance

1 Week
 
 28.82%
 
1 Month
 
 47.50%
 
3 Months
 
 237.53%
 
1 Year
 
 N/A
 
5 Years
 
 N/A
 

SMDPY Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings
Full Ratings ➔
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Sumitomo Dainippon Pharma - SMDPY

Collapse All in section
All values USD millions. 2022 2023 2024 2025 5-year trend
Sales/Revenue
4.98B 4.10B 2.18B 2.62B
Sales Growth
+2.46% -17.72% -46.89% +20.11%
Cost of Goods Sold (COGS) incl D&A
1.68B 1.57B 1.09B 1.14B
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
341.28M 304.61M 261.51M 167.67M
Depreciation
- - 101.91M 88.28M
-
Amortization of Intangibles
- - 239.37M 216.32M
-
COGS Growth
+15.49% -6.62% -30.52% +4.34%
Gross Income
3.30B 2.53B 1.09B 1.48B
Gross Income Growth
-3.11% -23.36% -57.04% +35.92%
Gross Profit Margin
+66.28% +61.73% +49.94% +56.51%
2022 2023 2024 2025 5-year trend
SG&A Expense
2.80B 2.45B 1.10B 1.33B
Research & Development
844.59M 973.39M 779.96M 327.09M
Other SG&A
1.96B 1.48B 317.96M 1.00B
SGA Growth
+1.28% -12.54% -55.17% +21.26%
Other Operating Expense
- - - -
-
Unusual Expense
(21.10M) 1.03B 2.44B 49.18M
EBIT after Unusual Expense
524.40M (948.96M) (2.45B) 97.90M
Non Operating Income/Expense
241.06M 618.53M 244.83M 73.76M
Non-Operating Interest Income
1.63M 33.31M 13.98M 5.84M
Equity in Earnings of Affiliates
- - - (5.94M)
-
Interest Expense
27.14M 23.32M 29.62M 56.14M
Interest Expense Growth
+11.33% -14.09% +27.00% +89.54%
Gross Interest Expense
27.14M 23.32M 29.62M 56.14M
Interest Capitalized
- - - -
-
Pretax Income
738.31M (353.75M) (2.24B) 115.52M
Pretax Income Growth
+0.59% -147.91% -532.49% +105.16%
Pretax Margin
+14.81% -8.63% -102.72% +4.42%
Income Tax
376.99M 360.20M (56.68M) (39.51M)
Income Tax - Current - Domestic
391.41M 289.49M (23.57M) (109.90M)
Income Tax - Current - Foreign
- - - -
-
Income Tax - Deferred - Domestic
(14.42M) 70.71M (33.11M) 70.38M
Income Tax - Deferred - Foreign
- - - -
-
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - (5.94M)
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
361.32M (713.95M) (2.18B) 155.03M
Minority Interest Expense
(140.73M) (163.90M) 276.98K 6.56K
Net Income
502.05M (550.05M) (2.18B) 155.03M
Net Income Growth
-5.28% -209.56% -296.51% +107.11%
Net Margin Growth
+10.07% -13.41% -100.13% +5.93%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
502.05M (550.05M) (2.18B) 155.03M
Preferred Dividends
- - - -
-
Net Income Available to Common
502.05M (550.05M) (2.18B) 155.03M
EPS (Basic)
1.2637 -1.3845 -5.4897 0.3902
EPS (Basic) Growth
-5.28% -209.56% -296.51% +107.11%
Basic Shares Outstanding
397.29M 397.29M 397.29M 397.29M
EPS (Diluted)
1.2637 -1.3845 -5.4897 0.3902
EPS (Diluted) Growth
-5.28% -209.56% -296.51% +107.11%
Diluted Shares Outstanding
397.29M 397.29M 397.29M 397.29M
EBITDA
844.57M 387.31M 251.29M 314.75M
EBITDA Growth
-1.62% -54.14% -35.12% +25.25%
EBITDA Margin
+16.95% +9.44% +11.54% +12.03%

Sumitomo Dainippon Pharma in the News